ライフサイエンスコーパス: erythema

1 es exhibited a clinical score of 1 (pinpoint erythema).

2 nt is often initiated by symptoms or visible erythema.

3 , consisting mainly of infusion syndrome and erythema.

4 ced more TTs than UVA1 for the same level of erythema.

5 eukocyte markers, while quantifying clinical erythema.

6 pital because of cough, sputum, pruritus and erythema.

7 on site pain and tenderness, induration, and erythema.

8 delivery, but are sometimes associated with erythema.

9 cant reductions in gingival inflammation and erythema.

10 four patients experienced only minimal skin erythema.

11 SpeB- strains appeared pale with surrounding erythema.

12 ility and reproducibility for both scale and erythema.

13 rized by epidermal hyperplasia, scaling, and erythema.

14 ndoscopy showing areas of nonspecific patchy erythema.

15 0%]), alopecia (18 [19%] vs eight [4%]), and erythema (18 [19%] vs five [3%]).

16 and as tenderness (33 [66%] of 50 [51-79]), erythema (20 [40%] of 50 [26-55]), and pruritus (41 [82%

17 local adverse events with imiquimod included erythema (27%), scabbing or crusting (21%), flaking (9%)

18 mon adverse events were again injection-site erythema (33 [8%] of 416 with 50 mg sirukumab every 4 we

19 ory tract infection (8%), and injection-site erythema (6%).

20 eported injection site pain (52% vs 17%) and erythema (73% vs 25%) more frequently than placebo recip

21 acterized by less transient and nontransient erythema, a more lateral distribution of erythema and te

22 ter an immediate allergic reaction including erythema, abdominal pain, vomiting, and anaphylactic sho

23 , 28-53 years of age), the mean reduction in erythema across six doses of UVR (300-800 mJ/cm(2) in 10

24 a decrease in ulceration (alpha = 0.068) and erythema (alpha = 0.005) at the mid-point with continued

25 A 35-year-old male presented with erythema and burning pain in the hands since early child

26 inant, disorder characterized by generalized erythema and cutaneous blistering at birth followed by h

27 epresentations of the skin areas involved in erythema and edema, respectively.

28 Clinical examination exhibited erythema and enlargement of the interdental papillae bet

29 erized by recurrent episodes of palmoplantar erythema and epidermal peeling.

30 patients (50.2%), followed by injection site erythema and fatigue in 227 (25.6%) and 212 patients (23

31 (100g), he experienced nausea, wheezing, and erythema and had visited our hospital.

32 in the 1 g idarucizumab group (infusion site erythema and hot flushes), one in the 5 g plus 2.5 g ida

33 enotype consisting of early-onset patches of erythema and hyperkeratosis, as well as SCA manifesting

34 ed cutaneous immunity based on the extent of erythema and induration after intradermal VZV antigen in

35 Transient erythema and induration were more common after intraderm

36 Old human subjects exhibited decreased erythema and induration, CD4(+) and CD8(+) T-cell infilt

37 Erythema and intense scratching developed 2-3 days befor

38 measurements confirmed the absence of local erythema and irritation.

39 s shown by the action spectra of UVR-induced erythema and nuclear DNA (nDNA) damage.

40 Erythema and oedema were more frequent with avotermin th

41 Low-grade erythema and pain at the injection site were the most co

42 d on the day of treatment, and short-lasting erythema and pain at the site of application were common

43 IPA increases skin blood flow without erythema and PG increased erythema with decreased skin b

44 een sunscreens' abilities to protect against erythema and photoimmunosuppression.

45 ed to PCV13 (facial diplegia, injection-site erythema and pyrexia, autoimmune hemolytic anemia, and s

46 The median overall score combining erythema and roughness/bumpiness was 3.0 (IQR, 2-4) for

47 for association with skin cGVHD involvement (erythema and sclerosis, skin symptoms), lacrimal dysfunc

48 to approximately 8-fold as measured by both erythema and sunburn cell formation.

49 t radiation dose-response curves for sunburn/erythema and suppression of the contact hypersensitivity

50 Facial erythema and telangiectasia are commonly associated with

51 Participants with ETR tended to have erythema and telangiectasia primarily on the central fac

52 ent erythema, a more lateral distribution of erythema and telangiectasia, less neurogenic mast cell a

53 Complete treatment of erythema and texture in KP may require diode laser treat

54 the cessation of spread of infection-related erythema and the absence of fever at 48 to 72 hours.

55 esponse (healing of erosions, improvement in erythema, and alleviation of pain), adverse effects, and

56 dema, lupus erythematosus [occurring twice], erythema, and dermohypodermitis all experienced by one [

57 sorders associated with generalized scaling, erythema, and epidermal barrier impairment.

58 Presence of epithelial desquamation, erythema, and erosions on gingival tissue is usually des

59 nces in vaccination take rates, lesion size, erythema, and induration or in serum neutralizing-antibo

60 of psoriasis-like plaques, generalized scaly erythema, and Koebner's phenomenon.

61 Erythema, and mechanical and thermal pain thresholds wer

62 ical diagnosis based on intermittent warmth, erythema, and pain in the distal extremities.

63 ical diagnosis based on intermittent warmth, erythema, and pain in the distal extremities.

64 Alopecia, injection site erythema, and pruritus were 13%, 27%, and 10%, respectiv

65 ies and were often associated with swelling, erythema, and pruritus.

66 taken and analyzed for areas of ulceration, erythema, and reticulation.

67 disease (higher and more sustained viremia, erythema, and thrombocytopenia).

68 uman-like disease, including fever, viremia, erythema, and thrombocytopenia.

69 is, grade 1 erythema multiforme, and grade 3 erythema; and grade 2 infusion-related reaction.

70 edema in mice, and reduced susceptibility to erythema arising from narrow-band 311-nm UVR in humans.

71 EtOH and ButOH increase erythema as a function of skin blood flow.

72 dpoint was a >/=20% reduction in the area of erythema at 48-72 hours in the intent-to-treat populatio

73 were reported aside from mild and transient erythema at site of treatment.

74 at the mid-point with continued reduction of erythema at the final (alpha = 0.075) time measurement.

75 the drug's side effects, including pain and erythema at the infusion site.

76 ion level, which contrasts strongly with the erythema-based sun protection factors (mainly indicative

77 sers have been used to reduce the associated erythema but not the textural irregularity.

78 Findings included eyelid swelling and erythema, conjunctival chemosis, pain on eye movement, m

79 ction characterized by respiratory distress, erythema, decreased body temperature, unresponsiveness,

80 rate cutaneous inflammation characterized by erythema, dermal infiltrates of CD45(+) leukocytes, and

81 Impact on skin erythema, dermal leukocytic infiltration, and concentrat

82 Subsequently, a dose-related erythema developed at treatment sites by 3 hours and per

83 ( Fig 1 ), there was generalized periareolar erythema, dimpling, firmness, and fixation involving the

84 irradiated with UVB (three times, 1 minimal erythema dose (80 mJ/cm(2)), weekly) for 10 weeks, and e

85 ts and 11 controls were exposed to 1 minimum erythema dose (MED) of UVR delivered from Waldmann UV-6

86 -UVB) regimens start with 70% of the minimal erythema dose (MED) with 20% increments at each treatmen

87 s that measured time-related UVR in standard erythema dose (SED) and corresponding sun diaries (mean,

88 rotein changes in the skin after one minimal erythema dose of spectrally pure UVA1 (50 J cm(-2)) and

89 in vivo by looking at changes in the minimal erythema dose with subsequent doses of UV radiation.

90 ion, median (IQR) sunburn threshold (minimal erythema dose) was 28 (20-28) and 20 (20-28) mJ/cm(2) in

91 during the study was 39.1 (30.9) as standard erythema dose, comparable to a quarter of the median sum

92 lated radiation, ranging from 0 to 2 minimum erythema dose, on gluteal skin, with or without sunscree

93 uence the 24 hour minimal phototoxic dose or erythema dose-response.

94 Individual minimal erythema doses (MED) for each source were determined and

95 wk later were exposed to 0.75 and 2 minimum erythema doses (MED) of SSR on the upper inner arm.

96 t-radiation of either 0, 0.6, 1 or 2 minimal erythema doses (MED).

97 exposures ranging from 0.65 to 3.9 standard erythema doses (SEDs), which were equivalent to 15-90 mi

98 n between our subjects' UVB and UVA1 minimal erythema doses implies that UVA1 and UVB erythema occur

99 Rash or erythema due to APM was reported in 7 (37%) patients, al

100 nically important differences in tendency to erythema during a standard 70/20% NB-UVB twice-weekly re

101 Side effects, including the development of erythema during phototherapy, were similar for the two l

102 Topically applied PAO induces cutaneous erythema, edema and micro-blisters.

103 ats exhibited a clinical score of 2 (diffuse erythema/edema).

104 narof leads to compound-driven reductions in erythema, epidermal thickening, and tissue cytokine leve

105 was related to documented EDEL (category 1: erythema/erosion; category 2: ulcer).

106 No epithelial erythema, erosions, or ulcerations were seen.

107 Thus, erythema following alcohol exposure is alcohol type spec

108 common after intradermal administration (31% erythema for full subcutaneous dose and 77% for intrader

109 se events in this period were injection-site erythema (four [1%] with placebo, 22 [8%] with 50 mg sir

110 Pulsed-dye laser was used for pruritus and erythema; fractional CO2 laser was used for stiffness an

111 sis bullosa simplex with migratory circinate erythema (frameshift mutation c1649delG in the V2 domain

112 VA protection, especially against cumulative erythema from repeated suberythemal exposure.

113 eria at follow-up visits: fever; increase in erythema (>25%), swelling, or tenderness (days 3-4); no

114 ommon adverse events were diarrhoea, rash or erythema, hepatic adverse events, and neutropenia (not r

115 s: fever, dehiscence, foul smell, peri-wound erythema, hypotension, and leukocytosis.

116 Area Severity Index (IASI), which integrates erythema (IASI-E) and scaling (IASI-S); transepidermal w

117 ticipants (78%) in the umbrella group showed erythema in 1 or more sites vs 10 of the 40 participants

118 traviolet radiation, measured objectively as erythema in a sample of 12 body sites on 15 Northern Eur

119 Notable adverse events included erythema in both groups and minor infections and nausea

120 nvestigated UV-induced sunburn apoptosis and erythema in mouse skin as a function of circadian time.

121 GE(2), PGF(2alpha), and PGE(3) accompany the erythema in the first 24-48 h, associated with increased

122 All cases presented with pain and periocular erythema increasing over approximately 1 week.

123 h no difference in AUC analysis for measured erythema index after a geometric series of 10 UVR doses.

124 xtensively evaluated in vivo as a measure of erythema induced in human skin and is expressed as Sun P

125 asured by dermal microdialysis and cutaneous erythema), induces an intense epidermal infiltrate of ma

126 There were more local reactions (pain, erythema, induration, and warmth) and systemic reactions

127 of human diseases, including fifth disease (erythema infectiosum) in children and pure red cell apla

128 trick skin types I through III, but baseline erythema is not improved.

129 Keratolytic winter erythema (KWE) is a rare autosomal-dominant skin disorde

130 over 3 mo did not significantly reduce skin erythema, leukocyte infiltration, or eicosanoid response

131 aracterized by transient figurate patches of erythema, localized or generalized scaling, and frequent

132 The degree of erythema may also be useful since a normal color makes o

133 lar pain (100%), sleep disturbances (75.3%), erythema migrans (59.7%), headache (46.8%), fatigue (44.

134 ri DNA in skin samples from 90 patients with erythema migrans (EM) and in synovial fluid (SF) from 63

135 ic-treated patients, 53% with culture-proven erythema migrans (EM) had IgG responses to recombinant g

136 fection causes an initial skin lesion called erythema migrans (EM) in human Lyme disease and in model

137 elia burgdorferi spreads in the skin to form erythema migrans (EM) lesions and then disseminates to o

138 hese inflammatory responses in patients with erythema migrans (EM) or Lyme arthritis (LA) to elucidat

139 l manifestation of early Lyme disease is the erythema migrans (EM) skin lesion that develops at the t

140 allel, analyzed B. burgdorferi isolates from erythema migrans (EM) skin lesions in 91 patients, and c

141 urgdorferi genotypes have been isolated from erythema migrans (EM) skin lesions in patients with Lyme

142 bjective was to obtain data on patients with erythema migrans (EM) who have symptoms/signs suggesting

143 ltiplex assays in the serum of patients with erythema migrans (EM), joint fluid of patients with Lyme

144 stage LD but is insensitive in patients with erythema migrans (EM), the most common manifestation of

145 n subjects with Lyme disease presenting with erythema migrans alone (n=36), erythema migrans with neu

146 symptoms was compared between patients with erythema migrans and 81 control subjects without a histo

147 confirmed early LD, based on the presence of erythema migrans and documentation of seroconversion or

148 course of oral doxycycline for treatment of erythema migrans and for a 14-day course for treatment o

149 5 consecutive patients with the diagnosis of erythema migrans and reported original data regarding th

150 variability in the clinical presentation of erythema migrans and the need to factor in multiple comp

151 Patients with erythema migrans and underlying hematological malignancy

152 sitive patients with Lyme disease-associated erythema migrans and were evaluated for an association w

153 chetemia explain why untreated patients with erythema migrans are at risk for dissemination of B. bur

154 Lyme disease patients with erythema migrans are said to have post-treatment Lyme di

155 Blood was obtained from patients with erythema migrans before (n = 29) and 2 months after (n =

156 from 17 patients who received a diagnosis of erythema migrans between 1991 and 2011 and who had 22 pa

157 ive for B. burgdorferi DNA in a patient with erythema migrans early during therapy and in a patient w

158 ent evidence supports treating patients with erythema migrans for no longer than 10 days when doxycyc

159 of the early steps of Borrelia invasion and erythema migrans formation after tick bite.

160 0-day doxycycline treatment in patients with erythema migrans has been assessed in the United States

161 ents with early Lyme disease associated with erythema migrans have a positive blood culture based on

162 Our data show that repeat episodes of erythema migrans in appropriately treated patients were

163 Erythema migrans is the most common manifestation of Lym

164 Lyme disease as either a clinician-diagnosed erythema migrans lesion or a positive standard 2-tiered

165 4.2%; P = 0.006) and more often had multiple erythema migrans lesions (41.9% vs. 15.0%; P < 0.001) th

166 dorferi genotypes in cells and patients with erythema migrans or Lyme arthritis.

167 the frequency of nonspecific symptoms among erythema migrans patients was similar to that among cont

168 arious MTTT protocols in patients with acute erythema migrans ranged from 36% (95% confidence interva

169 bite from an Ixodes scapularis tick and the erythema migrans rash associated with Lyme disease.

170 9 (MMP-9) was selectively upregulated in the erythema migrans skin lesions of patients with acute Lym

171 afzelii, or Borrelia garinii recovered from erythema migrans skin lesions of patients with Lyme borr

172 patients with culture-confirmed episodes of erythema migrans to distinguish between relapse and rein

173 Concomitant erythema migrans was registered in 104 of 144 patients (

174 Patients with multiple erythema migrans were almost uniformly culture positive

175 one of the 22 paired consecutive episodes of erythema migrans were associated with the same strain of

176 study assessed whether repeated episodes of erythema migrans were due to the same or different strai

177 Similarly, serum samples from patients with erythema migrans who were infected with the RST1 genotyp

178 Adult patients with erythema migrans with a positive skin or blood culture f

179 esenting with erythema migrans alone (n=36), erythema migrans with neurological disease (n=12), and c

180 s with probable LD, based on the presence of erythema migrans without documented seroconversion or of

181 86 antibiotic-treated European patients with erythema migrans, 45 with post-Lyme symptoms and 41 with

182 urteen-day antibiotic treatment, as used for erythema migrans, is effective.

183 cells from 27 patients with culture-positive erythema migrans, production of inflammatory cytokines p

184 No studies included patients without erythema migrans, so specificity data and likelihood rat

185 Among 311 patients with erythema migrans, the frequency of coinfection with HGA

186 n 11 (28%) of 39 of subjects presenting with erythema migrans, which increased to 50% at 4 weeks of f

187 Erythema migrans, while not pathognomonic, is the most c

188 a large (>/=5-cm diameter) rash, known as an erythema migrans.

189 ents after completing antibiotic therapy for erythema migrans.

190 s with early Lyme disease who presented with erythema migrans.

191 Lyme disease was defined by the presence of erythema migrans.

192 received standard courses of antibiotics for erythema migrans.

193 among adult European patients with solitary erythema migrans.

194 d from patients with consecutive episodes of erythema migrans.

195 re evaluated in adult European patients with erythema migrans.

196 hly sensitive by itself for the diagnosis of erythema migrans.

197 ination characteristics for the diagnosis of erythema migrans.

198 nhance therapeutic efficacy in patients with erythema migrans.

199 ies to B. burgdorferi in patients with acute erythema migrans.

200 h a compatible clinical syndrome but without erythema migrans.

201 ed with longer illness duration and multiple erythema migrans.

202 eatment-matched immunocompetent persons with erythema migrans.

203 City with early Lyme disease associated with erythema migrans; it is the largest number of borrelial

204 determined using serum from 55 patients with erythema migrans; specificity was determined using serum

205 s were well tolerated in the skin, with mild erythema, minimal wheal formation and complete resolutio

206 -independent, cascade of events resulting in erythema, mixed dermal infiltrate, and epidermal hyperpl

207 Injection site pain, itching, and erythema (mostly mild) were the only solicited adverse e

208 Adverse events, mainly rash, pruritus, erythema, mouth and tongue disorders, and taste alterati

209 Herpes simplex virus (HSV)-associated erythema multiforme (HAEM) is a recurrent disease charac

210 pothyroidism; grade 3 iridocyclitis, grade 1 erythema multiforme, and grade 3 erythema; and grade 2 i

211 eumonitis, localized myositis, folliculitis, erythema multiforme, or ophthalmological manifestations.

212 on-eczematous contact dermatitis include the erythema multiforme-like, the purpuric, the lichenoid, a

213 een administration routes for injection-site erythema (n=10 [12%] and n=0, respectively) and nausea (

214 ts in the vitespen group were injection-site erythema (n=158) and injection-site induration (n=153).

215 rface area and UVB exposure dose, related to erythema, necessary to achieve a given level of vitamin

216 ed oral ulcers (100%), genital ulcers (62%), erythema nodosum (46%), and papulopustular lesions (54%)

217 ease course (Pcombined = 5.94 x 10(-7)), and erythema nodosum (Pcombined = 2.27 x 10(-6)), respective

218 osition -308 was found to be associated with erythema nodosum in Caucasian sarcoidosis patients (stud

219 a gene adjacent to TNF, was associated with erythema nodosum in female Caucasian sarcoidosis patient

220 rcoidosis and may explain the higher rate of erythema nodosum in females with sarcoidosis.

221 ariant has individually been associated with erythema nodosum in sarcoidosis patients.

222 e is clinically valuable in the treatment of erythema nodosum leprosum (ENL) and multiple myeloma and

223 nts when evaluated before the onset of acute erythema nodosum leprosum (ENL) and persistently elevate

224 g thalidomide is the treatment of choice for erythema nodosum leprosum (ENL), an inflammatory cutaneo

225 In erythema nodosum leprosum (ENL), which occurs in patient

226 immune reactions, reversal reaction (RR) and erythema nodosum leprosum (ENL).

227 pted by acute inflammatory episodes known as erythema nodosum leprosum (ENL).

228 associated with increased susceptibility to erythema nodosum leprosum in an allelic analysis, wherea

229 sal) reactions and 124 patients with type 2 (erythema nodosum leprosum) reactions.

230 s "reactional states" (reversal reaction and erythema nodosum leprosum) that result in major clinical

231 lammatory and autoimmune disorders including erythema nodosum leprosum, Behcet's syndrome, discoid lu

232 an investigational agent in the treatment of erythema nodosum leprosum, oral ulcers, graft versus hos

233 wn role in inflammation were associated with erythema nodosum status in 659 sarcoidosis patients and

234 noted: fever, sialadenitis, lymphadenopathy, erythema nodosum, leukocytoclastic vasculitis, transient

235 nt oral and genital ulceration, uveitis, and erythema nodosum.

236 She had neither erythema nor internal organ involvements.

237 mal erythema doses implies that UVA1 and UVB erythema occur by different mechanisms.

238 ed erythema, the number of treatments before erythema occurred did not differ between skin types (P=0

239 e drug eruptions, viral exanthema, and toxic erythema of chemotherapy, Demodex folliculitis is a clin

240 tis was defined as either pus discharge with erythema of the abdominal skin or severe redness (>2 cm

241 were characterized by reversible oedema and erythema of the graft.

242 ever, bilateral nonexudative conjunctivitis, erythema of the lips and oral mucosa, changes in the ext

243 dmitted to our hospital because of fever and erythema on the face and extremity.

244 (aOR 5.17, 95% CI 1.9-14.1), abdominal wall erythema or discolouration at presentation (aOR 2.51, 95

245 o the absence of inflammatory signs, such as erythema or scaling.

246 n with placebo included injection site pain, erythema, or both (21 [20%] of 107 vs seven [6%] of 110)

247 se (31% prevalence) was associated with skin erythema (P < 0.001); salivary dysfunction (11% prevalen

248 over 30 years of age and is characterized by erythema, papulopustules and telangiectasia.

249 Reduced UV-B means less erythema, plant damage, and slower photolysis rates.

250 r Scale (VSS), which documents pigmentation, erythema, pliability, and height, and (2) University of

251 ty results in immune protection that exceeds erythema protection.

252 rate transient injection-site reactions (eg, erythema, pruritus) were the most frequent IMA901-relate

253 nal treatment, presence of serous discharge, erythema, purulent exudate, separation of the deep tissu

254 significantly correlated with sizes of SPT (erythema: r=0.645, urticaria: r=0.657).

255 an increase in body temperature (fever) and erythema (rash) in comparison with humanized mice inocul

256 l (ie, patch-site) adverse events (including erythema, rash, pruritus, hyperpigmentation, pain, hypop

257 ed skin blood flow (Doppler velocimeter) and erythema (reflectance colorimeter a*) following topical

258 The sensitivity changes broadly followed the erythema response and did not extend beyond the irradiat

259 Here we show that erythema resulting from UVR is a comprehensive and nonin

260 inical response to broadband UVA, comprising erythema+/-scaling plaques (17/20).

261 the dermatological sum score (DSS) assessing erythema, scaling, and plaque elevation on a 4-point sca

262 e selected based on ARC symptom severity and erythema skin prick reaction to short ragweed.

263 assessed, showing nonerosive lesions such as erythema, swelling, and lymphoid hyperplasia in 8 patien

264 ry card where any subjective adverse events (erythema, swelling, itching, headache, root hypersensiti

265 palpation of her joints, without associated erythema, swelling, or crepitus.

266 enderness (days 8-10); and more than minimal erythema, swelling, or tenderness (days 14-21).

267 ng, or tenderness (days 3-4); no decrease in erythema, swelling, or tenderness (days 8-10); and more

268 ve much better protection against cumulative erythema than the UVB sunscreen.

269 To our knowledge, the dusky erythema that occurred in the 3 patients described here

270 Index for Ichthyosis Severity for scale and erythema that provides (1) written descriptions of the f

271 n skin disorder of follicular prominence and erythema that typically affects the proximal extremities

272 Among patients who developed erythema, the number of treatments before erythema occur

273 UV radiation were pigmentation, scaling, and erythema; the most frequent dermoscopic changes were inc

274 d, although more frequent infusion site pain/erythema/thrombophlebitis was seen with fosaprepitant re

275 for cancer, and ranges in severity from mild erythema to moist desquamation and ulceration.

276 ation (18 [44%]), xerosis (8 [20%]), scrotal erythema/ulceration (6 [15%]), and nail splinter hemorrh

277 ied by headache, myalgias, nausea, diarrhea, erythema, vasodilatation, and hypotension.

278 bcutaneous tissue, presenting with expanding erythema, warmth, tenderness, and swelling.

279 Nontransient erythema was also greater in the ETR group (50% graded m

280 the proportion of patients who had developed erythema was approximately 60% regardless of MED.

281 Erythema was assessed by eye and objectively, and the SP

282 Ultraviolet-radiation-induced erythema was comparable in patients and controls.

283 Transient erythema was greater in the ETR group (38% graded modera

284 By contrast, the interrater reliability for erythema was higher during in-person validation compared

285 tential genetic basis for alcohol-associated erythema was investigated as the function of polymorphis

286 Erythema was quantified using a reflectance meter and al

287 Moderate erythema was reported by 9 patients after DPDT and 14 pa

288 eactions occurred in most patients, but only erythema was significantly more common in the VGX-3100 g

289 Injection-site erythema was the most commonly coded term for non-seriou

290 PG-induced erythema was uniquely associated with tumor necrosis fac

291 Median length and width of erythema were 13.0 cm and 10.0 cm.

292 ptosis, inflammatory cytokine induction, and erythema were maximal following an acute early-morning e

293 (AEs), predominantly manifested by pruritus, erythema, wheal, or eczema.

294 ting 14g of boiled jellyfish, he experienced erythema, wheezing, nausea, and abdominal pain.

295 tly responsible for the necrolytic migratory erythema, which resolves after amino acid administration

296 was commensurate with development of palatal erythema, which suggests a role for biofilm in the infla

297 ts, one from each group, reported persistent erythema, which was considered to be possibly related to

298 signs are skin lesions (necrolytic migratory erythema), while in subjects with inactivating mutations

299 blood flow without erythema and PG increased erythema with decreased skin blood flow, all as a functi

300 oM) each produced perceptible induration and erythema with moderate cellular infiltration resolving w